Hence, routine determination and evaluation of CEA and LDH levels, prior to each cycle of platinum‐based chemotherapy in advanced NSCLC, should be considered as part of daily clinical practice. The gene discussed is CEACAM5; the disease is non-small cell lung carcinoma.